Table S4. Overlapping of the included systematic reviews and meta-analysis

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Systematic reviews and meta-analyses | | | | | | | | | | | | | | | | | | |
| **Original research** | [Song et al, 2011](https://www.liebertpub.com/doi/10.1089/jop.2011.0017?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed) | [Li et al,](https://pubmed.ncbi.nlm.nih.gov/?term=Li+SM&cauthor_id=24445721)2014 | [Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+C&cauthor_id=34925913) et al, 2021 | [Gan](https://pubmed.ncbi.nlm.nih.gov/?term=Gan+J&cauthor_id=35096861) et al, 2022 | [Gong](https://pubmed.ncbi.nlm.nih.gov/?term=Gong+Q&cauthor_id=28494063) et al, 2017 | [Lanca](https://pubmed.ncbi.nlm.nih.gov/?term=Lanca+C&cauthor_id=37033047) et al, 2023 | [Tran](https://pubmed.ncbi.nlm.nih.gov/?term=Tran+HDM&cauthor_id=34456234) et al, 2021 | [Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+N&cauthor_id=33678055) et al, 2022 | [Zhao](https://pubmed.ncbi.nlm.nih.gov/?term=Zhao+C&cauthor_id=33287746) et al, 2020 | [Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+NN&cauthor_id=35919929) et al, 2022 | [Gao et al, 2021](https://journals.lww.com/claojournal/pages/articleviewer.aspx?year=2021&issue=02000&article=00007&type=Fulltext) | [Wei](https://pubmed.ncbi.nlm.nih.gov/?term=Wei+XL&cauthor_id=37602338) et al, 2023 | [Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+S&cauthor_id=32781450) et al, 2020 | [Wang et al, 2023](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0282286) | [Tsai](https://www.mdpi.com/2077-0383/10/17/3766) et al, 2021 | [Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+W&cauthor_id=36123161) et al, 2022 | [Kumari et al,](https://pubmed.ncbi.nlm.nih.gov/?term=Kumari+S&cauthor_id=36993096)2022 | [Fan et al, 2021](http://ies.ijo.cn/gjykcn/article/abstract/202105022?st=search) | [Zhang et al, 2023](https://www.sciencedirect.com/science/article/abs/pii/S0181551223000281) |
| [Yen et al. 1989](https://pubmed.ncbi.nlm.nih.gov/2742290/)[1] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Shih et al. 1999](https://pubmed.ncbi.nlm.nih.gov/10048351/)[2] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Chua et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16996612/)[3] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| [Chia et al. 2012](https://pubmed.ncbi.nlm.nih.gov/21963266/)[4] | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| [Yi et al. 2015](https://pubmed.ncbi.nlm.nih.gov/26228967/)[5] | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| [Wang et al. 2017](https://pubmed.ncbi.nlm.nih.gov/28682887/)[6] | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| [Yam 2019](https://pubmed.ncbi.nlm.nih.gov/30514630/)[7] | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| [Yam et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32019700/)[8] | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Yam et al. 2022](https://pubmed.ncbi.nlm.nih.gov/34627809/)[9] | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Wei et al. 2020](https://pubmed.ncbi.nlm.nih.gov/33001210/)[10] | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| [Zhu et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32038101/)[11] | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Saxena et al. 2021](https://pubmed.ncbi.nlm.nih.gov/33545170/)[12] | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| [Hieda et al. 2021](https://pubmed.ncbi.nlm.nih.gov/33586090/)[13] | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| [Bedrossian et al. 1985](https://pubmed.ncbi.nlm.nih.gov/4011150/)[14] | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Chou et al. 1997](https://pubmed.ncbi.nlm.nih.gov/9029440/)[15] | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Kennedy et al. 2000](https://pubmed.ncbi.nlm.nih.gov/11486796/)[16] | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Lee et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16503774/)[17] | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Fan et al. 2007](https://pubmed.ncbi.nlm.nih.gov/17295137/)[18] | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Fang et al. 2010](https://pubmed.ncbi.nlm.nih.gov/20698798/)[19] | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Wu et al. 2011](https://pubmed.ncbi.nlm.nih.gov/21815829/)[20] | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Lin et al. 2013](https://pubmed.ncbi.nlm.nih.gov/24212187/)[21] | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Clark et al. 2015](https://pubmed.ncbi.nlm.nih.gov/26218150/)[22] | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| [Lee et al. 2016](https://pubmed.ncbi.nlm.nih.gov/27435576/)[23] | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Polling et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32958872/)[24] | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Moon et al. 2018](https://pubmed.ncbi.nlm.nih.gov/30364238/)[25] | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Larkin et al. 2019](https://pubmed.ncbi.nlm.nih.gov/31602553/)[26] | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| [Sacchi et al. 2019](https://pubmed.ncbi.nlm.nih.gov/31197953/)[27] | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| [Fu et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32086237/)[28] | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| [Liang et al. 2008](https://pubmed.ncbi.nlm.nih.gov/19028329/)[29] | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Hsiao et al. 2005](https://pubmed.ncbi.nlm.nih.gov/16206249/)[30] | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Shih et al. 2001](https://pubmed.ncbi.nlm.nih.gov/11401629/)[31] | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Brodstein et al. 1984](https://pubmed.ncbi.nlm.nih.gov/6514306/)[32] | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Diaz-Llopis et al. 2018](https://pubmed.ncbi.nlm.nih.gov/29398233/)[33] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Kumaran et al. 2015](https://pubmed.ncbi.nlm.nih.gov/26313301/)[34] | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Tan et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32776533/)[35] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Tang et al. 2020](https://search.bvsalud.org/gim/resource/en/wpr-876809)[36] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Tong et al. 2009](https://pubmed.ncbi.nlm.nih.gov/19167081/)[37] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Zhao et al. 2021](https://pubmed.ncbi.nlm.nih.gov/33205372/)[38] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| [Lin et al. 2014](https://pubmed.ncbi.nlm.nih.gov/24685184/)[39] | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Chen et al. 2019](https://pubmed.ncbi.nlm.nih.gov/30482510/)[40] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Wan et al. 2018](https://pubmed.ncbi.nlm.nih.gov/30205439/)[41] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Tan et al. 2019](https://pubmed.ncbi.nlm.nih.gov/30632410/)[42] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Kinoshita et al. 2018](https://pubmed.ncbi.nlm.nih.gov/29974278/)[43] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Vincent et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32888318/)[44] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Kinoshita et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32728111/)[45] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Zhao et al. 2021](https://pubmed.ncbi.nlm.nih.gov/32620344/)[46] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Luo et al. 2021](https://pesquisa.bvsalud.org/portal/resource/pt/wpr-837714)[47] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Zhou et al. 2021](https://pubmed.ncbi.nlm.nih.gov/34228946/)[48] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Chen et al. 2020](https://pubmed.ncbi.nlm.nih.gov/33707188/)[49] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Shi et al. 2017](https://kns.cnki.net/kcms2/article/abstract?v=kMpVSI0yL5e4WybC_Vkk2fuxkVrH5GbNYw_YTm1kh7OPigGpkPAH-gHEf-rjEIMXPQPBdZs9TLhRZrzjmdBzM-L9mFD2ZGjBHkSE8_x4dFc-NOsldYf2li52FIC1Dyasy7D-V1XxCz0zK3wcd6j3kA==&uniplatform=NZKPT)[50] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Hao et al. 2021](https://pubmed.ncbi.nlm.nih.gov/33954859/)[51] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Zhao et al. 2021](https://kns.cnki.net/kcms2/article/abstract?v=kMpVSI0yL5dQ4276iV5pAyfWU3n2DY2HKMzFSZMTqpB6GY8slqNSonSaLil2zTGIgiuCuS4EkUTEm1HfM22w1Od2jLTcswWIIrnVdoclpgs427ALRXZR22QTM90sIB8YtB8XIPTPdLQDikTeVgtcPw==&uniplatform=NZKPT)[52] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Zhang et al. 2021](https://kns.cnki.net/kcms2/article/abstract?v=kMpVSI0yL5ddlNX5yFtpkyWLUHClEJiHZkSNwalTqzQbAzbueT_YFhcKk1dbmNRRsmIVIUPtb0V3BbuB6pxmzOQmEEbFkRAQtu-W9QyGIDMUPMm2GMJY9--hKgY5YPIzLlblg8lPBDtEXsPmMriENw==&uniplatform=NZKPT)[53] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Cui et al. 2021](https://pubmed.ncbi.nlm.nih.gov/34782708/)[54] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Wang et al. 2022](https://pubmed.ncbi.nlm.nih.gov/35184254/)[55] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Shi 2018](https://kns.cnki.net/kcms2/article/abstract?v=kMpVSI0yL5fzAxa2ytZjc7fh4NUgK0SkJQimfjeBWdJZ9Fr6_i-qQdZ3tCaW45k_gb_BdBH58-x135zVRF_fXLiUQ2KtuYZCZEBb55OyghU-dqMziLiAFBGrJn805YcffTThmIv36t0=&uniplatform=NZKPT)[56] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Ji et al. 2022](https://pubmed.ncbi.nlm.nih.gov/34924543/)[57] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Jiang 2018](http://ies.ijo.cn/gjykcn/article/abstract/201807046)[58] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Ren et al. 2017](http://ies.ijo.cn/gjykcn/article/abstract/201704057)[59] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| [Niu et al. 2019](http://ies.ijo.cn/gjykcn/article/abstract/201911029)[60] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| [Cui 2017](https://kns.cnki.net/kcms2/article/abstract?v=kMpVSI0yL5e_7Uc1GO8ZLCZWdudZsasdNsWJ3FBm_KHZmPQShSNsYdZf8izrbSXqLvW6cabKl-Cqp0F94RoAPnclMnjAUGfWoHAHyPQ1zZvkLddN3-4ENfh3jCdJmphwhBf-yPzvPZ_WAENyiD8LEg==&uniplatform=NZKPT)[61] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| [Zheng et al. 2020](https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjMwODMxEg9sY3lrenoyMDIwMDYwMTQaCGVmNWFseDVw)[62] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| [Rong et al. 2020](https://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_ykyj202006013&dbid=WF_QK)[63] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| [Meng 2020](https://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_hgzy202001032&dbid=WF_QK)[64] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| [Shen et al. 2020](https://kns.cnki.net/KXReader/Detail?invoice=wBIoEKlszeHtcFy%2F0Z%2BREOZKC7z8jZrn4tLisdjS18NpBvIKKmj5CGpVQ5%2BUgBLXXDxDuWWNpVqsBO05AO6RbwTAQHTY%2B%2BSba%2BUUbstBia6RHMd8cESWjDVwsHNPA%2BnPy5Q2Etid2C%2BL2U1q62YnwYTVc8p1fjt%2FQfeN%2FDyBeR4%3D&DBCODE=CJFD&FileName=SXYY202009033&TABLEName=cjfdlast2020&nonce=7DCBCDE80DCE4964BE1AC9288A44D63E&TIMESTAMP=1697618145455&uid=)[65] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| [Liu et al. 2020](https://kns.cnki.net/KXReader/Detail?invoice=cL17%2FeuvhICx%2B3wStNtTOs08nGyRtctDtFgrtU5BrVYv7BVDKP5DNrGyqP3jdnwtODVJTqcVc5iLMFOtPBKL5HpaEbzUtsoQ8ywtRycjli2FyIb3ip1%2BvSsTZ0WeP7zmEnqktP4gdUf6iLaXiAgekgdHhb3igkfPKDcbicGcYAg%3D&DBCODE=CJFQ&FileName=SXYY202005042&TABLEName=cjfdlast2020&nonce=D50B47BFA4E44CB09C71B48484425474&TIMESTAMP=1697619819578&uid=)[66] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| [Li et al. 2018](https://kns.cnki.net/KXReader/Detail?invoice=nloUKcS1BQG1dRl0ltHzEt0ZdUbcuPb9wKxqL44WJQNYHKSyhNB8oAr1wbzKLADZgaVMI7mYzHlvpkT3HjVo%2FddP8N4M5RjH6fy96Lg%2FXGNOYcHZB3QnrBJbgfB%2Fp2GDqZ9zI7fDj9ZZHXVz08ai8qxLYL1K1%2BdcORgervnTXoo%3D&DBCODE=CJFD&FileName=XIWS201803035&TABLEName=cjfdlast2018&nonce=081136EDC751497D9344A566D6AAC28D&TIMESTAMP=1697619969060&uid=)[67] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| [Zhu et al. 2019](https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjMwODMxEg96amxjeXgyMDE5MDYwMzIaCGpocWdiZ213)[68] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |

**References**

1. Yen MY, Liu JH, Kao SC, Shiao CH: **Comparison of the effect of atropine and cyclopentolate on myopia**. *Ann Ophthalmol* 1989, **21**(5):180-182, 187.

2. Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT: **Effects of different concentrations of atropine on controlling myopia in myopic children**. *J Ocul Pharmacol Ther* 1999, **15**(1):85-90.

3. Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D: **Atropine for the treatment of childhood myopia**. *Ophthalmology* 2006, **113**(12):2285-2291.

4. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D: **Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)**. *Ophthalmology* 2012, **119**(2):347-354.

5. Yi S, Huang Y, Yu SZ, Chen XJ, Yi H, Zeng XL: **Therapeutic effect of atropine 1% in children with low myopia**. *J aapos* 2015, **19**(5):426-429.

6. Wang YR, Bian HL, Wang Q: **Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial**. *Medicine (Baltimore)* 2017, **96**(27):e7371.

7. Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ *et al*: **Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control**. *Ophthalmology* 2019, **126**(1):113-124.

8. Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ *et al*: **Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report**. *Ophthalmology* 2020, **127**(7):910-919.

9. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL *et al*: **Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report**. *Ophthalmology* 2022, **129**(3):308-321.

10. Wei S, Li SM, An W, Du J, Liang X, Sun Y, Zhang D, Tian J, Wang N: **Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial**. *JAMA Ophthalmol* 2020, **138**(11):1178-1184.

11. Zhu Q, Tang Y, Guo L, Tighe S, Zhou Y, Zhang X, Zhang J, Zhu Y, Hu M: **Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children**. *Int J Med Sci* 2020, **17**(2):176-181.

12. Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, Swaminathan M, Phuljhele S, Velpandian T, Sharma N: **Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial**. *Ophthalmology* 2021, **128**(9):1367-1369.

13. Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, Takahashi H, Nakamura Y, Sotozono C, Oshika T *et al*: **Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study**. *Jpn J Ophthalmol* 2021, **65**(3):315-325.

14. Bedrossian RH: **The treatment of myopia with atropine and bifocals: a long-term prospective study**. *Ophthalmology* 1985, **92**(5):716.

15. Chou AC, Shih YF, Ho TC, Lin LL: **The effectiveness of 0.5% atropine in controlling high myopia in children**. *J Ocul Pharmacol Ther* 1997, **13**(1):61-67.

16. Kennedy RH, Dyer JA, Kennedy MA, Parulkar S, Kurland LT, Herman DC, McIntire D, Jacobs D, Luepker RV: **Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students**. *Binocul Vis Strabismus Q* 2000, **15**(3 Suppl):281-304.

17. Lee JJ, Fang PC, Yang IH, Chen CH, Lin PW, Lin SA, Kuo HK, Wu PC: **Prevention of myopia progression with 0.05% atropine solution**. *J Ocul Pharmacol Ther* 2006, **22**(1):41-46.

18. Fan DS, Lam DS, Chan CK, Fan AH, Cheung EY, Rao SK: **Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: a pilot study**. *Jpn J Ophthalmol* 2007, **51**(1):27-33.

19. Fang PC, Chung MY, Yu HJ, Wu PC: **Prevention of myopia onset with 0.025% atropine in premyopic children**. *J Ocul Pharmacol Ther* 2010, **26**(4):341-345.

20. Wu PC, Yang YH, Fang PC: **The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren**. *J Ocul Pharmacol Ther* 2011, **27**(5):461-466.

21. Lin L, Lan W, Liao Y, Zhao F, Chen C, Yang Z: **Treatment outcomes of myopic anisometropia with 1% atropine: a pilot study**. *Optom Vis Sci* 2013, **90**(12):1486-1492.

22. Clark TY, Clark RA: **Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia**. *J Ocul Pharmacol Ther* 2015, **31**(9):541-545.

23. Lee CY, Sun CC, Lin YF, Lin KK: **Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study**. *BMC Ophthalmol* 2016, **16**:114.

24. Polling JR, Tan E, Driessen S, Loudon SE, Wong HL, van der Schans A, Tideman JWL, Klaver CCW: **A 3-year follow-up study of atropine treatment for progressive myopia in Europeans**. *Eye (Lond)* 2020, **34**(11):2020-2028.

25. Moon JS, Shin SY: **The diluted atropine for inhibition of myopia progression in Korean children**. *Int J Ophthalmol* 2018, **11**(10):1657-1662.

26. Larkin GL, Tahir A, Epley KD, Beauchamp CL, Tong JT, Clark RA: **Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample Across Three US Sites**. *Ophthalmol Ther* 2019, **8**(4):589-598.

27. Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, Nucci P: **Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients**. *Acta Ophthalmol* 2019, **97**(8):e1136-e1140.

28. Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, Ji N, Lyu Y: **Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression**. *Br J Ophthalmol* 2020, **104**(11):1535-1541.

29. Liang CK, Ho TY, Li TC, Hsu WM, Li TM, Lee YC, Ho WJ, Cheng JT, Tzeng CY, Liu IT *et al*: **A combined therapy using stimulating auricular acupoints enhances lower-level atropine eyedrops when used for myopia control in school-aged children evaluated by a pilot randomized controlled clinical trial**. *Complement Ther Med* 2008, **16**(6):305-310.

30. Hsiao CK, Tsai MY, Chen HM: **Inference of nested variance components in a longitudinal myopia intervention trial**. *Stat Med* 2005, **24**(21):3251-3267.

31. Shih YF, Hsiao CK, Chen CJ, Chang CW, Hung PT, Lin LL: **An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression**. *Acta Ophthalmol Scand* 2001, **79**(3):233-236.

32. Brodstein RS, Brodstein DE, Olson RJ, Hunt SC, Williams RR: **The treatment of myopia with atropine and bifocals. A long-term prospective study**. *Ophthalmology* 1984, **91**(11):1373-1379.

33. Diaz-Llopis M, Pinazo-Durán MD: **Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness**. *Arch Soc Esp Oftalmol (Engl Ed)* 2018, **93**(4):182-185.

34. Kumaran A, Htoon HM, Tan D, Chia A: **Analysis of Changes in Refraction and Biometry of Atropine- and Placebo-Treated Eyes**. *Invest Ophthalmol Vis Sci* 2015, **56**(9):5650-5655.

35. Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P: **One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial**. *Ophthalmic Physiol Opt* 2020, **40**(5):557-566.

36. Tang W: **Clinical observation of low-dose Atropine combined with orthokeratology in the treatment of myopia**. *International Eye Science* 2020, **(12): 1044-1047**.

37. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH: **Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine**. *Ophthalmology* 2009, **116**(3):572-579.

38. Zhao Q, Hao Q: **Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children**. *Int Ophthalmol* 2021, **41**(3):1011-1017.

39. Lin HJ, Wan L, Tsai FJ, Tsai YY, Chen LA, Tsai AL, Huang YC: **Overnight orthokeratology is comparable with atropine in controlling myopia**. *BMC Ophthalmol* 2014, **14**:40.

40. Chen Z, Huang S, Zhou J, Xiaomei Q, Zhou X, Xue F: **Adjunctive effect of orthokeratology and low dose atropine on axial elongation in fast-progressing myopic children-A preliminary retrospective study**. *Cont Lens Anterior Eye* 2019, **42**(4):439-442.

41. Wan L, Wei CC, Chen CS, Chang CY, Lin CJ, Chen JJ, Tien PT, Lin HJ: **The Synergistic Effects of Orthokeratology and Atropine in Slowing the Progression of Myopia**. *J Clin Med* 2018, **7**(9).

42. Tan Q, Ng AL, Cheng GP, Woo VC, Cho P: **Combined Atropine with Orthokeratology for Myopia Control: Study Design and Preliminary Results**. *Curr Eye Res* 2019, **44**(6):671-678.

43. Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A: **Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results**. *Jpn J Ophthalmol* 2018, **62**(5):544-553.

44. Vincent SJ, Tan Q, Ng ALK, Cheng GPM, Woo VCP, Cho P: **Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control**. *Ophthalmic Physiol Opt* 2020, **40**(6):728-737.

45. Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, Kakehashi A: **Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial**. *Sci Rep* 2020, **10**(1):12750.

46. Zhao W, Li Z, Hu Y, Jiang J, Long W, Cui D, Chen W, Yang X: **Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness**. *Cont Lens Anterior Eye* 2021, **44**(3):101348.

47. Luo Y: **Clinical observation of orthokeratology combined with 0.01% Atropine for controlling low to moderate myopia in adolescents**. *International Eye Science* 2021, **(12): 47-52**.

48. Zhou H, Zhao G, Li Y: **Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia**. *Clin Exp Optom* 2022, **105**(5):520-526.

49. Chen Z, Zhou J, Xue F, Qu X, Zhou X: **Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children**. *Br J Ophthalmol* 2022, **106**(8):1069-1072.

50. Shi Y: **Effect of orthokeratology lens combined with 0.01% atropine on juvenile myopia**. *Journal of Chinese Practical Diagnosis and Therapy* 2017, **31(11),1102-1103**.

51. Hao Q, Zhao Q: **Changes in subfoveal choroidal thickness in myopic children with 0.01% atropine, orthokeratology, or their combination**. *Int Ophthalmol* 2021, **41**(9):2963-2971.

52. Zhao D: **Study on the treatment of myopia with anticholonergic drugs combined with night orthokeratology**. *Journal of Huanghe S&T College* 2021, **23(08),42-46**.

53. Zhang Y: **Effect of 0.01% atropine combined with orthokeratology on the control of middle and low myopia in adolescents**. *Journal of China Prescription Drug* 2021, **19(11),121-124**.

54. Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, Rong J, Bai Y, Fu A: **Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial**. *Sci Rep* 2021, **11**(1):22267.

55. Wang Y, Zhu X, Xuan Y, Wang M, Zhou X, Qu X: **Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children**. *Ophthalmol Ther* 2022, **11**(2):833-856.

56. Shi M: **The synergistic effects of orthokeratology combined with 0.01% atropine in slowing the progression of juvenile myopia**. *HeNan China Zhengzhou Univ Ppl Hosp* 2018, **p. 1–41**.

57. Ji N, Niu Y, Qin J, Fu AC, Cui C: **Orthokeratology Lenses Versus Administration of 0.01% Atropine Eye Drops for Axial Length Elongation in Children With Myopic Anisometropia**. *Eye Contact Lens* 2022, **48**(1):45-50.

58. Jiang J: **Effect of orthokeratology, low concentration atropine and frame glasses on juvenile myopia prevention and control**. *International Eye Science* 2018, **18(07),1349-1352**.

59. Ren Q: **Effects of low concentration atropine and orthokeratology on myopia prevention and control**. *International Eye Science* 2017, **17(4):794-796**.

60. Niu Y: **Effect of low grade Atropine combined with keratoplasty on middle grade myopia in adolescents**. *International Eye Science* 2019, **19(11):1940-1944**.

61. Cui Y: **Clinical research progress of 0.01% atropine in delaying children's myopia**. *China Health Standard Management* 2017, **8(22),79-80**.

62. Zheng J: **Effect of 0.01% atropine eye drops on controlling myopia and accommodation function adolescents** *Journal of Clinical Ophthalmology* 2020, **28**:533-537.

63. Rong J: **Clinical effect of 0.01% atropine eye drops on myopia progression in school-age children**. *Chinese Journal of Experimental Ophthalmology* 2020, **38(6)**.

64. Meng R: **Analysis of the Effectiveness of 0.01％ Atropine in Controlling Myopia Pro-gression**. *Chinese and Foreign Medical* 2020, **39(1)**.

65. Shen Y: **Observation of effect of 0.01% atropine in children's myopia control**. *Shanxi Medical Journal* 2020, **Shanxi Medical Journal**.

66. Liu Z: **Effect of 0.01% atropine in controlling adolescent myopia**. *Shanxi Medical Journal* 2020, **49(05),591-592**.

67. Li J: **Prevention of myopia onset and progression with 0.01% atropine solution among school-age children**. *Chinese Journal of School Health* 2018, **39(03),432-435**.

68. Zhu X: **Efficacy of low concentration atropine on myopic juvenile patients with different diopter**. *Zhejiang Clinical Medical Journal* 2019, **21(6), 806-808**.